AI-driven drug discovery for neuroscience and metabolic diseases
insitro pairs machine learning with wet-lab biology to find disease drivers and design therapeutics. Its stack spans PyTorch, Ray and Spark on AWS, GCP and Azure, alongside Benchling, LIMS, Nextflow and Tecan automation, which points to an industrialized data-to-lab loop. Senior- and director-heavy hiring in engineering and research, plus Phase 1 trial design work, signals a shift from platform building toward clinical execution.
insitro is a privately held biotechnology company founded in 2018 and headquartered in South San Francisco, California. It combines large-scale human and cellular data with machine learning models to identify genetic causes of disease and design candidate medicines. Its therapeutic pipeline focuses on neuroscience and metabolic diseases. The company has 201–500 employees, and its current hiring is concentrated in the United States across engineering, research, data and legal functions.
insitro uses Python, PyTorch, TensorFlow, Ray, Dask, Apache Spark, Airflow, Nextflow and Snakemake. It runs on AWS, GCP and Azure with Kubernetes and Argo CD, plus Benchling, LIMS, RDKit and Tecan for lab workflows.
Current work includes Phase 1 trial design and execution, an iPSC-CM platform, a CellML platform, an optical screening platform, bioassay development and ML-powered computer vision pipelines.
Yes. Engineering is insitro's largest hiring area, followed by research and data. Hiring skews toward senior and director-level roles and is based in the United States.
Other companies in the same industry, closest in size
insitro's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.